Entera Bio Ltd. will be presenting new clinical data from its Phase 2 trial of EB613 at the NAMS 2025 Annual Meeting in Orlando. The presentation will focus on bone mineral density outcomes in early postmenopausal women with low bone mass or osteoporosis over six months. EB613 is the first oral anabolic tablet, offering potential to broaden access for women with osteoporosis. The Phase 2 study showed positive results in increasing bone formation markers and BMD without safety concerns. Entera Bio is dedicated to developing oral peptide and protein replacement therapies to transform the standard of care for various medical needs. Entera Bio highlights important factors affecting their forward-looking statements, including clinical data interpretation and FDA review processes. The company emphasizes potential market growth for product candidates in various disease categories. Entera acknowledges risks related to regulatory approvals, intellectual property protection, and financial liquidity. Investors are cautioned not to rely solely on forward-looking statements. The company commits to updating information as required by law. For further details, contact Chief Executive Officer Miranda Toledano at [email protected].

Read more at 1. “Apple unveils new iPhone 13 models with improved cameras and longer battery life.” – CNBC
2. “CDC recommends Pfizer booster shots for certain groups, including healthcare workers and older adults.” – Wall Street Journal
3. “Amazon announces plans to hire 55,000 employees for corporate and tech roles.” – Reuters
4. “Tesla’s Elon Musk says company will begin production of electric ‘robotaxi’ next year.” – CBS MarketWatch: Entera Bio to Present New Clinical Data from Phase 2 Trial